Novartis/Aventis Merger Would Pair Rx-to-OTC Experience With Allegra
This article was originally published in The Tan Sheet
Executive Summary
Novartis would bring a proven track record in Rx-to-OTC switches to a combination with the French pharmaceutical firm Aventis
You may also be interested in...
Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”
A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands